Dr. Subba R. Digumarthy, MD
Radiology (Diagnostic Radiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 3,221
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Diagnostic Radiology Physician primary
MA license 218599
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
- Martha's Vineyard Hospital Inc Oak Bluffs, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 3,221
- Services billed
- 7,625
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,579 | 206 |
| Injection, gadoterate meglumine, 0.1 ml | 3,870 | 22 |
| X-ray of chest, 1 view | 1,854 | 1,215 |
| Ct scan of chest with contrast | 1,150 | 987 |
| Ct scan of chest without contrast | 766 | 721 |
| X-ray of chest, 2 views | 214 | 210 |
| Ct scan of blood vessels of chest with contrast | 115 | 115 |
| Low dose ct scan of chest for lung cancer screening | 99 | 99 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,500 in total to this clinician.
| Siemens Medical Solutions USA, Inc. | $1,500 |
|---|
| Consulting Fee | $1,500 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Siemens Medical Solutions USA, Inc. Jan 23, 2025 | Consulting Fee NAEOTOM Alpha · CT and RO incl. Computed Tomography and Radiation Oncology | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $297,170 in research payments for these studies, mostly to the institutions running them.
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05625399 - Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim Espana S.a. - A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT03873402 - A phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with …
AstraZeneca UK Limited - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05409066 - Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Active, not recruiting · NCT06158841 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo…
AstraZeneca UK Limited - A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnos…
AstraZeneca UK Limited - A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Terminated · NCT05513703 - A randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.